Guillain-Barré syndrome is generally referred to as Guillain-Barré syndrome, with initial reactions such as dyskinesia and dysesthesia. Guillain-Barré syndrome is a self-limiting disease, and patients tend to have an acute onset of the disease, with symptoms peaking in about 2 weeks. Usually, in the early stage of Guillain-Barré syndrome, the patient’s body is accompanied by symptoms of discomfort, such as muscle weakness, limb paralysis and other motor disorders, sensory disorders such as burning and tingling sensations in the skin of the limbs, as well as symptoms of autonomic dysfunction such as redness of the skin, sweating and other symptoms. Some patients with Guillain-Barré syndrome may also experience tachycardia, swelling of the hands and feet, urination or defecation disorders, blurred vision, photophobia, nausea and vomiting, diarrhea, bloating, and other uncomfortable symptoms, which tend to reduce the quality of life and affect the health status of the organism. If the patient does not pay attention to the disease, leading to further progression, but also prone to respiratory failure, tachyarrhythmia and other complications. It is recommended that patients with Guillain-Barré syndrome seek medical attention as soon as possible and standardize their treatment under the guidance of a professional physician in order to improve their discomfort and promote the return of normal movement or sensation.